SoutarRL, WilsonBJ, DawsonAA. Incidence and mortality trends for multiple myeloma over thirty years in North East Scotland. Health Bull1996; 54:232–40.
2.
KyleRA. Multiple myeloma: review of 869 cases. Mayo Clin Proc1975; 50:29–40.
3.
McCloskeyEV, O'RoukeN, MacLennanI. Natural history of skeletal disease in multiple myelomatosis and treatment with Clodronate. Bone Miner1992; 17 (supplement 1):61.
4.
ClarkA, ShettyA, SoutarR. Myeloma and renal failure. Blood Rev1999; 13:79–90.
5.
Valentin-OpranA, CharhonS, MeunierPJ. Quantitative histology of myeloma-induced bone changes. Br J Haematol1982; 52:601–10.
6.
TaubeT, BenetonMNC, McCloskeyEV. Abnormal bone remodeling in patients with myelomatosis and normal biochemical indices of bone resorption. Eur J Haematol1992; 49:192–8.
7.
KanisJA, McCloskeyEV. Disorders of calcium and skeletal metabolism. In: MalpasJS, BergsagelDE, KyleR, AndersonK (eds). Myeloma: biology and management. Oxford: Oxford Medical Publications; 1998; 358–80.
8.
KleinB. Growth factors in the pathogenesis of multiple myeloma. In: GhartonG, DurieBGM (eds). Multiple myelomaLondon: Arnold;, 1996;73–82.
9.
WahnerHW, KyleRA, BeaboutJW. Scintigraphic evaluation of the skeleton in multiple myeloma. Mayo Clinic Proc1980; 55:739–46.
10.
RahmouniA, DivineM, MathieuD. Detection of multiple myeloma involving the spine: efficacy of fat suppression and contrast-enhanced MR imaging. AJR1993; 160:1049–52.
11.
WoolfendenJM, PittMJ, DurieBGM. Comparison of bone scintigraphy in multiple myeloma. Radiology1980; 134:723–8.
12.
BatailleR, ChevalierJ, RossiM. Bone scintigraphy in plasma-cell myeloma. Radiology1982; 145:801–4.
13.
McCloskeyEV. Bone protection in myeloma. Current Medical Literature, Leukaemia and Lymphoma1998; 6(1):3–10.
14.
HarleyJB, SchillingA, GlidewellO. Acute Leukemia Group B and the Eastern Cooperative Oncology Group. Ineffectiveness of fluoride therapy in multiple myeloma. N Eng J Med1972; 286:1283–8.
15.
CohenHJ, SilbermanHR, TorynosK. for the Southeastern Cancer Study Group. Comparison of two long-term chemotherapy regimens, with or without agents to modify skeletal repair, in multiple myeloma. Blood1984; 63:639–48.
16.
BelchAR, BergsagelDE, WilsonK. Effect of daily etidronate on the osteolysis of multiple myeloma. J Clin Oncol1991; 9:1397–402.
17.
LahtinenR, LaaksoM, PalvaI. Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Lancet1992; 340:1049–52.
18.
BerensonJ, LichtensteinA, PorterL. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Eng J Med1996; 334:488–93.
McCloskeyEV, MacLennanICM, DraysonMT. A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. Br J Haematol1998; 100:317–25.
21.
RalstonSH, PatelU, FraserWD. Comparison of three intravenous bisphosphonates in cancer-associated hypercalcaemic. Lancet1989; 2:1180–2.
22.
PurohitOP, RadstoneCR, AnthonyC. A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy. Br J Cancer1995; 72:1289–93.
23.
BatailleR, ChappardD, MarcelliC. The recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma. J Clin Invest1991; 88:62–6.
24.
LaaksoM, LahtinenR, VirkkunenP. for the Finnish Leukaemia Group. Subgroup and cost-benefit analysis of the Finnish multicentre trial of clodronate in multiple myeloma. Br J Haematol1994; 87:725–9.
25.
BruceNJ, McCloskeyEV, KanisJA. Economic impact of using clodronate in the management of patients with multiple myeloma. Br J Haematol1999; 104:358–64.
26.
NCCN practice guidelines for multiple myeloma. Oncology (Hunting)1998; 12(11A):317–51.
27.
PurohitOP, AnthonyC, RadstoneCR. High-dose intravenous pamidronate for metastatic bone pain. Br J Cancer1994; 70:554–8.
28.
PriceP, HoskinPJ, EastonD. Prospective randomised trial of single and fractionated radio-therapy schedules in the treatment of painful bony metastases. Radiother Oncol1986; 6:247–55.
29.
SamsonD. Principles of chemotherapy and radiotherapy. In: GhartonG, DurieBGM (eds). Multiple myelomaLondon: Arnold,, 1996;108–29.
30.
OsterborgA, MellstedtH. Clinical features and staging. In: GhartonG, DurieBGM (eds). Multiple myelomaLondon: Arnold,, 1996;98–107.
31.
O'DonoghueDS, HowellA, BundredNJ, WallsJ. Orthopaedic management of structurally significant bone destruction in breast cancer bone metastases. J Bone Joint Surg1997; 79B (supplement 1):98.
32.
GalaskoCSB. Surgical stabilisation often provided good pain relief. BMJ1997; 315:186.
33.
AttalM, HarousseauJ-L, StoppaA-M. A prospective randomised trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Eng J Med1996; 335:91–7.
34.
BerensonJR, LiptonA, RosenLS. Phase I clinical study of a new bisphosphonate, Zoledronate (CGP-42446), in patients with osteolytic bone metastases. Blood1996; 88 (supplement 1):2334.
35.
VerdonckLF, LokhorstHM, DekkerAW. Graft-versus-myeloma effect in two cases. Lancet1996; 347:800–1.
36.
ShipmanCM, RogersMJ, ApperleyJA. Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. Br J Haematol1997; 98:665–72.
37.
DhodapkarM, SinghJ, MehtaJ. Anti-myeloma activity of pamidronate in vivo. Br J Haematol1998; 103:530–2.
